Stay updated on Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-30T12:06:12.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.0, replacing the previous version 2.15.2.
    Difference
    0.2%
    Check dated 2025-05-23T07:25:19.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-05-01T23:29:06.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the removal of detailed study information regarding a trial for platinum-resistant Epithelial Ovarian Cancer, while adding references to collaborators and a new version revision.
    Difference
    47%
    Check dated 2025-04-17T10:52:03.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-10T05:27:20.000Z thumbnail image
  7. Check
    96 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-25T19:06:45.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page.